Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Bone neoplasm is an umbrella classification encompassing benign, intermediate, and malignant tumors arising from bone tissue or articular cartilage. The category spans a wide spectrum of biologically distinct entities, including benign lesions such as aneurysmal bone cysts and solitary bone cysts, malignant primary bone cancers such as Ewing sarcoma and peripheral primitive neuroectodermal tumors of bone, and hereditary forms such as hereditary multiple osteochondromas, Ollier disease, and diaphyseal medullary stenosis with bone malignancy syndrome. The onset category for this classification is recorded as late, reflecting that tumors within this heterogeneous group may manifest in later life.
Because bone neoplasm is a heterogeneous umbrella classification rather than a single disease entity, clinical features vary considerably depending on the specific subtype. No shared phenotype data are catalogued at the umbrella level of this classification in this packet. The particular signs and symptoms associated with any case are determined by the specific subtype, anatomic location, and biological behavior of the tumor involved.
The etiology across the bone neoplasm category is heterogeneous. Some recognized subtypes—including hereditary multiple osteochondromas, Ollier disease, and diaphyseal medullary stenosis with bone malignancy syndrome—have documented hereditary components. No shared causative gene or inheritance pattern is recorded at the umbrella level of this classification; both heritable and non-heritable processes are represented among the subtypes comprising this category.
Diagnostic approaches are subtype-specific across the bone neoplasm category. Active clinical trial activity includes studies of interventional devices for percutaneous musculoskeletal procedures and adaptive proton radiotherapy for pediatric solid tumors involving bone, reflecting the use of imaging-guided and procedural evaluation across this disease category.
Active clinical investigation spans multiple therapeutic modalities, including drug therapy, procedural interventions, medical devices, and gene therapy approaches. Ongoing trials include combination chemotherapy studies for Ewing sarcoma and neoadjuvant radiotherapy investigations for localized bone sarcomas. No FDA-approved treatments are catalogued at the umbrella disease level in this packet; therapeutic approaches across the subtypes are heterogeneous.
54 trials found
Outcomes within the bone neoplasm category vary substantially by subtype, histologic classification, and anatomic location. A published research base of 229 classified publications—with review and meta-analysis as the dominant literature type—reflects the diversity of summarized evidence across the constituent subtypes.
Forty-nine active clinical trials are registered for this disease category, with a mixed academic and industry sponsor profile including Actuate Therapeutics, Amgen, and Emerald Clinical. Investigational modalities include drug therapy, gene therapy, procedural interventions, and medical devices. Gene therapy publications and biomarker publications are present in the research landscape, and recent clinical trial publications are also represented across this category.
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center